CG
JSPR icon

Cutler Group’s Jasper Therapeutics JSPR Stock Holding History

Cutler Group’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-120
Closed – – 2962
2023
Q4 		$0 Hold
120
– – ﹤0.01% 3978
2023
Q3 		$0 Buy
120
+30
+33% +$366 ﹤0.01% 4066
2023
Q2 		$1K Hold
90
– – ﹤0.01% 3321
2023
Q1 		$1K Buy
+90
New +$1.66K ﹤0.01% 3462

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Cutler Group's JSPR Position: Q1 2024 in Review

Cutler Group sold out of Jasper Therapeutics (JSPR) in Q1 2024, closing a stake of 120 shares.

Cutler Group first reported a position in JSPR in Q1 2023 and held it in 4 quarters. The position peaked at $1K in Q2 2023. 61 funds tracked by Wall St. Rank hold JSPR as of Q1 2024.

  • Cutler Group reported no remaining Jasper Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 120 Jasper Therapeutics shares in Q1 2024.
  • Cutler Group first reported a position in Jasper Therapeutics in Q1 2023 and held it in 4 quarters.
  • Cutler Group's Jasper Therapeutics position peaked at $1K in Q2 2023.
  • 61 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.